Thanks for emailing that article!
San Francisco, CA, August 1, 2010 - Rhett M. Schiffman, MD, MS, MHSA, the Vice President of Global Drug Development and Therapeutic Area Head of Ophthalmology at Allergan, Inc., has joined the Board of Directors of the Glaucoma Research Foundation (GRF) in San Francisco.
Dr. Schiffman joined Allergan in 2001 and has had responsibility for the development and approval of numerous ophthalmic medications including RESTASIS®, ELESTAT®, ZYMAR®, ZYMAXID™, ACULAR LS® ACUVAIL®, COMBIGAN® and LUMIGAN® 0.01%.
“Rhett’s work as a clinician, researcher and teacher, along with his dedication to patient care through his work at Allergan, makes him an excellent addition to our Board,” said Thomas M. Brunner, President and CEO of the Glaucoma Research Foundation. “Allergan’s long-time support of our patient education program has helped countless glaucoma patients over many years. Rhett’s expertise on the Board of Directors will be a great asset.”
Dr. Schiffman received his BS in Bioengineering from Columbia University, School of Engineering and Applied Sciences and his MD from the University of Juarez, Mexico. He also received Master’s degrees in Clinical Research Design and Statistical Analysis and in Health Services Administration from the University of Michigan. He completed residencies in both Internal Medicine and Ophthalmology at Henry Ford Hospital and is Board Certified in both and also completed a Uveitis fellowship from the National Eye Institute at the National Institutes of Health.
In addition to his work for Allergan, Dr. Schiffman continues to see patients and teach residents at the University of California at Irvine where he is Associate Clinical Professor of Ophthalmology.
Last reviewed on October 29, 2017